Abstract Aggresomes are protein aggregates found in mammalian cells when the intracellular protein degradation machinery is over-titered. Despite that they abound in cells producing recombinant proteins of biomedical and biotechnological interest, the physiological roles of these protein clusters and the functional status of the embedded proteins remain basically unexplored. In this work, we have determined for the first time that, like in bacterial inclusion bodies, deposition of recombinant proteins into aggresomes does not imply functional inactivation. As a model, human α-galactosidase A (GLA) has been expressed in mammalian cells as enzymatically active, mechanically stable aggresomes showing higher thermal stability than the soluble GLA version. Since aggresomes are easily produced and purified, we propose these particles as novel functional biomaterials with potential as carrier-free, self-immobilized catalyzers in biotechnology and biomedicine.
Introduction
Contrarily to what had been previously stated, inclusion bodies (IBs) produced by recombinant bacteria are formed by biologically active polypeptides embedded in amyloid-like networks (Garcia-Fruitos et al. 2005; Tokatlidis et al. 1991; Worrall and Goss 1989) . The unexpected application of IBs as versatile, functional, and biocompatible materials paves the road for their use as self-immobilized catalysts when formed by enzymes like reductases (Garcia-Fruitos et al. 2005) , oxidases (Nahalka and Nidetzky 2007; Nahalka et al. 2008a ), kinases (Nahalka et al. 2006; Nahalka and Patoprsty 2009) , phosphorylases (Nahalka 2008) , and aldolases (Nahalka et al. 2008b) , or as therapeutic agents in protein replacement therapies when formed by therapeutic proteins (Cano-Garrido et al. 2013; Seras-Franzoso et al. 2013a , b, 2014 Vazquez et al. 2012) . Mammalian cells instead of bacteria are preferred factories for eukaryotic protein production, because of their ability to perform proper post-translational modifications. In the late 1990s, Johnston showed the accumulation of recombinant proteins in subcellular structures of mammalian cells, named Baggresomes^ (Johnston et al. 1998) . Aggresome formation has been attributed to a cellular response to misfolded, nonproteolyzed proteins that deposit around the microtubuleorganizing center (MTOC) by active transport on microtubules. Their formation is prevented by disruption of the dynein-dynactin complex, suggesting that dynein protein is the motor of this transport (Garcia-Mata et al. 1999) . Aggresomes show a surrounding cage of intermediate filament (IF) proteins, like vimentin (Johnston et al. 1998) , and contain proteasome subunits, ubiquitin, and chaperones, consistent with their formation in response to cellular stress. Apart from the main aggregated protein species, aggresomes also contain Hsc70, Hsp40 proteins Hdj1 and Hdj2, and the chaperonin TriC/TCP (Garcia-Mata et al. 1999; Johnston et al. 1998; Wigley et al. 1999 ). However, the most consistent components of aggresomes are intermediate filament proteins. Even though many efforts have been devoted to reveal formation mechanisms, composition, and biological roles of aggresomes (Garcia-Mata et al. 1999 Johnston et al. 1998 Johnston et al. , 2000 Junn et al. 2002; Kopito 2000; Kopito and Sitia 2000; Wigley et al. 1999) , putative functionality and biological activities of the proteins embedded within them have been so far basically unexplored.
In the present study, we demonstrate, for the first time, that mammalian cell aggresomes, like in the case of bacterial IBs, retain the biological activity of the forming recombinant protein. By taking the human α-galactosidase A (GLA) as a model, we have obtained fully active and functionally and mechanically stable aggresomes that perform very efficiently in enzymatic processes. These results are discussed in the context of emerging nanostructured materials that when being functional and biocompatible might have intriguing applications in biomedicine, in order to package functional proteins that, because of their post-translational modifications, cannot be produced in bacteria as functional IBs.
Material and methods

Production of recombinant GLA
The expression vector pOpinE-GLA encodes a full-length version of the human GLA gene, cloned into pOPINE plasmid (Berrow et al. 2007 ). The suspension-adapted human embryonic kidney (HEK) cell line FreeStyle™ 293-F (Invitrogen™, Life Technologies, ref. R790-07) was used to produce GLA by polyethylenimine (PEI)-mediated transient gene expression. Details of GLA production and purification have been previously described (Corchero et al. 2011 ).
Detection of recombinant GLA in transfected cells
To estimate GLA accumulation into different cellular fractions, 1-ml samples of transfected cells were harvested (3, 4, and 5 days after transfection) and centrifuged (15 min, 15, 000 rpm), and supernatants separated from cells. Cell pellets were resuspended in 1 ml of 0.01 M acetic acid, pH 4.5, and disrupted by sonication. After centrifugation (15 min, 15, 000 rpm), supernatant containing soluble intracellular fraction was separated, and pellet containing intracellular insoluble fraction was resuspended in 1 ml of 0.01 M acetic acid, pH 4.5. All these three samples were then analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and western blot developed with a rabbit anti-GLA s e r u m ( a -g a l A H -1 0 4 : s c -2 5 8 2 3 , S a n t a C r u z Biotechnology). Amounts of GLA in each fraction were estimated by comparison, after SDS-PAGE and western blot, with known amounts of a recombinant soluble GLA produced in our laboratory. Samples and GLA standards were ran in the same gel and processed as a set. Densitometric analyses were performed with Quantity One software (Bio-Rad Laboratories, Inc). Recombinant GLA present in the three fractions (extracellular, intracellular soluble, and intracellular insoluble) were used to estimate the Btotal^recombinant GLA produced (taken as 100 % of recombinant protein produced), and then the values from each fraction were compared to this BTotal^value to obtain the percentages shown in Table 1 .
Aggresome formation was also checked by transmission electronic microscopy (TEM). For that, a total of~10 7 cells were taken before transfection (as negative control) and at different times post-transfection. After centrifugation (5 min, 1200 rpm), cell pellets were resuspended in 2.5 ml of fixing solution (paraformaldehyde 2 %, glutaraldehyde 2.5 %). After fixation (15 min, at room temperature), samples were stored at 4°C until TEM analysis. Samples were observed in a JEM-1400 transmission electron microscope (JEOL) with a CCD GATAN ES1000W Erlangshen camera.
Aggresome purification
At 5 days post-transfection, the soluble, secreted GLA present in the culture medium was separated from cells by centrifugation (15 min, 15,000 rpm) of transfected cultures. Supernatants were removed and cell pellets were used to purify aggresomes. The protocol and Bdisrupting buffers^previ-ously described (Garcia-Mata et al. 1999) were used for cell lysis. Briefly, cell pellets were resuspended with either 2 % Triton X-100 in PBS, IPB (insoluble protein) buffer (10 mM Tris-HCl, pH 7.5, 5 mM EDTA, 1 % NP-40, 0.5 % deoxycholate, 150 mM NaCl), or RIPA (radioimmunoprecipitation assay) buffer (50 mM TrisHCl, pH 8, 1 % NP-40, 0.5 % deoxycholate, 0.1 % SDS, 150 mM NaCl). Since GLA is a lysosomal enzyme (with optimal activity at pH 4.5), it is likely that incubation in an To compare amounts of aggresomes recovered by using different disrupting buffers, equal volumes of purified aggresomes were analyzed by SDS-PAGE and further Coomasie staining and western blot.
Characterization of recombinant GLA aggresomes
Enzymatic activity of soluble GLA and aggresomes was assayed, in vitro, fluorometrically as described by Desnick (Desnick et al. 1973 ) and Mayes (Mayes et al. 1981) . Briefly, activity was assayed using as substrate 4-methylumbelliferyl-α-D-galactoside (4MUG, Sigma Chemical), at 2.46 mM in assay buffer (0.01 M acetic acid, pH 4.5). Reaction mixtures contained 100 μl substrate and 25 μl enzyme sample, in which purified aggresomes were diluted in acetic acid in order to assure readings falling within the standard curve range. Reactions took place in agitation (37°C, 1 h) and were stopped with 1.25 ml of 0.2 M glycine-NaOH (pH 10.4). The released product (4-methylumbelliferone, 4-MU) was determined by fluorescence measurement at 365 and 450 nm as excitation and emission wavelengths, respectively. Samples of commercial product 4-MU (Sigma Chemical) ranging from 5 to 500 ng/ml in 0.2 M glycine-NaOH buffer, pH 10.4, were used to obtain a calibration curve in order to transform fluorescence readings into product 4-MU concentration. Specific enzymatic activities are expressed as μmol 4-MU/h/mg protein.
To identify the main proteins detected by Coomasie staining in purified aggresomes, their corresponding bands were cut out from the stained gels and trypsin digested. The resulting peptides were analyzed (by Bpeptide mass fingerprint^) by matrix-assisted laser desorption/ionization (time-of-flight), MALDI-TOF, and their sequences compared to SwissProt 2011_03 database.
Size distribution of aggresomes was measured by dynamic light scattering (DLS) at 633-nm wavelength, combined with non-invasive backscatter technology (NIBS) in a DLS analyzer (Zetasizer Nano ZS, Malvern Instruments Limited, Malvern, UK). Dispersions of purified aggresomes were prepared by sonication (2 min, 0.5-s on/off cycles, room temperature), diluted in acetic acid buffer, and measured at 20°C without filtering. Mean value of three measurements was taken as the hydrodynamic aggresome diameter. The software used to analyze the data is derived from a deconvolution of the measured intensity autocorrelation function of the sample, using a non-negatively constrained least squares (NNLS) fitting algorithm (software provided by Malvern with the Zetasizer instrument). The Bmean intensity^of the peak obtained (instead of the z-average number) was used as an estimation of the aggresome diameter (in nm), since the z-average mean size can be sensitive to the presence of even small populations of big aggregates.
Purified aggresomes were also checked by scanning electronic microscopy (SEM). For that, they were deposited on Nuclepore™ Track-Etched polycarbonate membranes with pore size of 0.2 μm (Whatman Ltd., UK). Then, samples were fixed with 2.5 % glutaraldehyde in 0.1 M phosphate buffer (PB, pH 7.4), washed four times (10 min each) in 0.1 M PB, post-fixed in 1 % (w/v) osmium tetraoxide with 0.7 % ferrocyanide in PB, washed in water, dehydrated in an ascending ethanol series (50, 70, 80, 90 , and 95 % for 10 min each and two times with 100 % ethanol), and dried by critical point drying with CO 2 . Samples were mounted on adhesive carbon films and coated with gold. Images were taken with an EVO® MA 10 scanning electron microscope (Zeiss) at an accelerating voltage of 20 kV and an EDS Oxford INCA detector.
Spontaneous release of GLA from aggresomes
The putative spontaneous release of GLA enzyme from aggresomes when incubated at 37°C (that could interfere in reusability experiments) was checked. For that, aggresomes were incubated at 37°C in agitation. At different time points, samples were taken and centrifuged (15 min, 15,000 rpm) in order to separate aggresomes from solubilized GLA that could have been released to the supernatant. After centrifugation, supernatants were separated and remaining aggresomes resuspended in their original volume with 0.01 M acetic acid, pH 4.5. Finally, enzymatic activity and western blot of aggresomes and supernatants were performed.
Thermal stability of soluble GLA and aggresomes
Soluble GLA and aggresomes were diluted in 0.01 M acetic acid, pH 4.5, aliquoted and incubated at 37°C. At different time periods, samples were taken and directly submitted to the enzymatic activity test. In the aggresome samples, putative solubilized/released enzyme and enzyme still in the aggregated state were not separated, meaning that measured activities were the summary of those from both released and aggregated enzyme. Activity of the aliquots was compared to that determined for aliquots kept always at −80°C, used as a reference.
Reusability of GLA aggresomes
Before testing aggresome reusability, they were incubated for 1 h at 37°C, in agitation. Then, aggresomes were centrifuged (15 min, 15,000 rpm) to discard GLA spontaneously released to the supernatant. Aggresomes were resuspended in their original volume with 0.01 M acetic acid, pH 4.5. After that, reusability was evaluated by performing successive enzymatic activity measurements as described before. After each reaction cycle, aggresomes were recovered by centrifugation (15 min, 15, 000 rpm). Supernatants containing the reaction product were transferred to a tube with 1.25 ml of 0.2 M glycine-NaOH buffer (pH 10.4). The amount of product released was determined as mentioned before. Aggresomes were washed with assay buffer and resuspended again in 25 μl. Then, fresh substrate was added and, next, measurement was carried out and compared with the first round (defined as 100 %).
Results
GLA expression and formation of aggresomes
Expression and accumulation of GLA into the extracellular, and soluble and insoluble intracellular fractions were checked by SDS-PAGE and western blot, showing a progressive accumulation of GLA into these three cellular fractions (Fig. 1) . At day 5, the total, accumulated GLA reached >160 μg/ml. From that,~50 % corresponded to the soluble and secreted form of the enzyme, while the rest remained intracellular, either as soluble (10.6 %) or insoluble versions (40 %) ( Table 1) . Intracellular protein shows an apparent molecular weight slightly lower than that of the secreted form (Fig. 1) . Trypsin digestion of the band corresponding to GLA embedded into aggresomes and peptide mass fingerprint identified 12 sequences matching GLA theoretical sequence. From such 12 sequences, two of them (MQLRNPELHLGCALALR and NPELHLGCALALR) were located within the GLA signal peptide (residues 1-17 and 5-17, respectively).
GLA expression and accumulation into aggresomes were visualized by TEM (Fig. 2) . In contrast to images from cells before transfection (Fig. 2a, b) , images taken at 3 and 5 days post-transfection (Fig. 2c, f) revealed clearly visible aggregates throughout the cytoplasm, not present before transfection. Since all samples used to obtain TEM images (including cells before transfection) were treated simultaneously, with the same protocol and reagents, and moreover cytoplasmic protein aggregates are only seen after transfection (and therefore, after GLA expression), the structures identified as aggresomes are not expected to be an experimental artifact. Such aggregates are not homogeneous but formed by the selfassembly of smaller, repeated building blocks, consisting on spherical structures of~50-100 nm in diameter.
Purification of aggresomes
The amount and purity of recovered aggresomes were determined by SDS-PAGE and western blot. According to densitometric analysis of membranes, samples obtained with RIPA buffer contained the lowest GLA amounts, while the use of acetic acid disrupting buffer allowed to recover 1.3-, 1.5-, and 2-fold more recombinant protein within aggresomes than that found with Triton, IPB, and RIPA buffers, respectively. Presence of solubilizing agents, like SDS in RIPA buffer, could explain this fact, since some of the protein initially entrapped within aggresomes could be solubilized (and therefore lost from the insoluble fraction) during the purification process. Irrespective of the buffer used, protein patterns within such structures are essentially the same (not shown), suggesting that disruption buffer does not significantly affect aggresome purity and composition.
Enzymatic and architectonic characterization of aggresomes
Since large protein aggregates are typically monitored at 350-360 nm, and in order to avoid any interference in the enzymatic assay readings due to the presence of such aggregates, an absorbance spectra control (in the range of 300 to 450 nm) of 100-fold diluted aggresomes was performed, resulting in absorbance values <0.1. Therefore, no interference from aggresomes is expected when performing the GLA enzymatic assay. Performing the GLA enzymatic assay using GLA aggresomes as sample showed that aggregation and incorporation of GLA into aggresomes did not result into enzymatic inactivation, as shown in Table 2 . Aggresomes purified in acetic acid disrupting buffer clearly showed the highest specific activity, which is not surprising since pH of this buffer is optimal for GLA activity. The specific activities for the more active aggresomes and for soluble GLA (Corchero et al. 2011 ) were 1095 ± 33 and 1947 ± 259 μmol/h/mg protein, respectively. That means that GLA incorporated into aggresomes retains~56 % of the specific activity of its soluble counterpart. Taking into consideration these results, we chose the acetic acid disrupting buffer to purify functional aggresomes used next.
Size of aggresomes was determined by DLS. When checking the distribution of sizes of our samples, results showed in all samples the presence of one main peak (corresponding to more than 90-95 % of the sample intensity), and then in some cases, the presence of some impurities of higher sizes, but corresponding to very small populations (less than 5-10 %) in the sample (data not shown). Regarding the number of decays in the auto-correlation functions, our data performed always give a unique, single exponential decay function, indicative of the presence of a main population. After this single decay, signal showed in some cases some scattering very near to the x-axis, probably indicative of (and supporting) the presence of the above mentioned impurities in the form of Bbig^aggregates. The polydispersity indexes obtained were 0.446±0.023, 0.616±0.018, 0.685±0.043, and 0.328 ± 0.029 for Triton, IPB, RIPA, and Bacetic acidd isrupting buffers, respectively, indicative that samples are suitable for the dynamic light scattering (DLS) analysis.
Aggresomes purified by using the disrupting buffers previously described (Garcia-Mata et al. 1999) showed sizes around 1 μm of diameter: 792±111, 1037±38, and 915± 97 nm for Triton, IPB, and RIPA buffers, respectively (Table 2 ), in agreement with TEM observations (Fig. 2e, f) . Interestingly, DLS determination of aggresomes purified in acetic acid disrupting buffer resulted in higher values (1698 ±29 nm in diameter), in agreement with SEM images (Fig. 3) .
The spherical building blocks detected in TEM images were also clearly visible by SEM (see Fig. 3b ), confirming the Baggregate of aggregates^architecture of aggresomes. Structures seen in both TEM (within transfected cells) and SEM (protein aggregates already purified) show the same architecture: They seem to be formed by the coalescence of small aggregates (of about 50 nm), which is distinctive of aggresomes. However, the building blocks seen in SEM are not as tightly packed as those seen in TEM (compare Fig. 2f with Fig. 3b ).
Compositional analysis of aggresomes
Analysis of purified aggresomes by SDS-PAGE and further Coomasie staining showed that such protein aggregates are not completely pure. On the contrary, some other cell proteins co-aggregate with recombinant GLA during aggresomes formation, appearing later as contaminants in purified aggresomes. This allowed us to determine the nature of some of such contaminant proteins by cutting off from the stained gel the bands corresponding to these main contaminants. MALDI-TOF analysis was performed on the four (d)), and 5 days (panels (e), (f)) after transfection. White arrows point out individual aggresomes. In panels (d) and (f), closer views allow to distinguish the spherical building blocks that compose GLA aggresomes predominant proteins (according to Coomasie staining) found in purified aggresomes. Results confirmed that one of these bands corresponded to human GLA enzyme or its precursor. Finding GLA precursor within aggresomes was not surprising, since some unprocessed GLA molecules still containing the secretion peptide might be trapped within aggresomes. Chaperone Hsp70 was found associated to aggresomes in significant amounts. Also, tubulin (a protein marker for MTOC) and actin (the monomeric subunit of the cytoskeleton microfilaments) are important components of aggresomes.
Spontaneous solubilization of aggresomes
During the first hour of incubation at 37°C,~20-25 % of the GLA initially entrapped within aggresomes was released to the supernatant, indicative of a spontaneous protein solubilization and release. Afterward, the aggresomal fraction remained basically constant. This was confirmed by both the decrease of enzymatic activity in the insoluble fraction (Fig. 4a) in parallel with the appearance of activity in the supernatant (corresponding to solubilized enzyme) (Fig. 4b) . Enzyme solubilization during the first hour was also confirmed by western blot (Fig. 4c, d ).
Stability and reusability of aggresomes
Thermal stabilities of soluble GLA and aggresomes were compared by following their enzymatic activity after incubation in acetic acid buffer, at 37°C. A clearly higher stability of aggresomes was observed (Fig. 5a ), as the activity of soluble GLA decreased rapidly, with less than 5 % of activity remaining after 1 day. However, for aggresomes, 68 and 79 % of activity remained after 7 and 14 days, respectively. These results indicate that GLA embedded within the aggresomes is Bprotected^and more resistant to thermal inactivation than its soluble counterpart. According to our results, soluble GLA is very sensitive to heat inactivation. Therefore, putative released GLA from aggresomes, even if not separated from aggresomes before testing, is not expected to interfere significantly in the final enzymatic activity found for aggresomes, especially after several days at 37°C.
Regarding reusability (determined by successive enzymatic assays after aggresomes recovery from the reaction mixture by centrifugation), aggresomes are easily recovered and, according to the results, could be reused at least in five consecutive enzymatic assays. A 70 % of enzymatic activity still remained after five rounds (Fig. 5b) . Since aggresomes had been incubated for 1 h at 37°C and the spontaneously GLA released eliminated by centrifugation before starting the reusability experiments, this drop in the enzymatic activity along consecutive assays is probably due to loss of aggresomes during centrifugation steps.
Discussion
Through the production of a model GLA in recombinant mammalian cells, we have demonstrated, for the first time, that mammalian cell aggressomes retain at significant extent the biological activity of the forming protein, similarly to what had been observed in bacterial IB (Garcia-Fruitos et al. 2005 . Contrarily to the conventional view on these protein particles, this observation indicates that these protein clusters are not exclusively composed by misfolded proteins but probably by functional folding intermediates or by a mixture of misfolded and properly folded proteins. Since GLA incorporated into aggresomes shows~56 % of the specific activity of its soluble counterpart, the possibility of residual activity by cross-contamination with soluble enzyme during purification should be discarded. Interestingly, although it has been never quantitatively determined, GFP aggresomes are fluorescent (Garcia-Mata et al. 1999 Shimohata et al. 2002) , indicating that the GLA activity determined in the present study is not a peculiar case. According to solubilization experiments, around 20-25 % of the GLA initially entrapped within aggresomes is solubilized and released to the supernatant under mild conditions (as shown in Fig. 4) . The protein solubilized from aggresomes at early incubation times shows poor thermal stability and becomes heat-inactivated (Fig. 4b) soon after its release from the aggresome. The enzyme still remaining within aggresomes after 1 h of incubation seems to form a core highly resistant to solubilization. This Bbimodal^architecture of aggresomes might be functionally similar to that proposed for bacterial IBs, in which a fraction of functional releasable protein coexists with mechanically stable, non-functional versions of the same protein (Cano-Garrido et al. 2013) . Probably related to such conformational heterogeneity, GLA aggregates are formed by the assembly of smaller, repeated building blocks consisting on spherical structures of~50-100 nm in diameter (Fig. 3) . This aggresome architecture, called aggregate of aggregates, is in agreement with previous reports (Garcia-Mata et al. 1999; Ioannou et al. 1992; Kopito 2000; Kopito and Sitia 2000) . According to this model, aggresome building blocks are produced throughout the cytoplasm by polypeptide coaggregation into single aggresomal particles or building blocks. In cells, such particles have a regular size (GarciaMata et al. 1999; Johnston et al. 2000) , supporting the idea that a fixed number of peptides aggregate form these building blocks. After their formation, these particles are transported to the MTOC, where they incorporate into the final, single aggresome. Electron microscopy has confirmed that building particles are loosely associated with each other and do not coalesce (Garcia-Mata et al. 1999; Johnston et al. 1998) . A similar model have been described for IB formation in Escherichia coli: For example, expression of asparaginase resulted in the formation, within an individual cell, of a high number of small aggregates which further loosely associate among themselves to form bigger aggregates (Upadhyay et al. 2012) .
Analysis of purified aggresomes showed that such protein aggregates are not completely pure. On the contrary, some impurities are co-purified with aggregated recombinant GLA. The presence of such contaminants that co-aggregate within eukaryotic aggresomes is not unexpected and has been previously described in the literature. Chaperone Hsp70 was found associated to aggresomes. In this regard, the role of Hsp70 in promoting aggresome formation has been described (Zhang and Qian 2011) , based on the Hsp70 interaction with the cochaperone ubiquitin ligase carboxyl terminal of Hsp70/ Hsp90 interacting protein (CHIP). Disruption of such Hsp70-CHIP interaction prevents aggresome formation, whereas a dominant-negative CHIP mutant sensitizes the aggregation of misfolded protein. In another study, Wang described the presence of Hsp70 associated to polyQ aggregates produced in yeast (Wang et al. 2007 ). Also, tubulin and actin are important components of aggresomes. The presence of cytoskeleton-associated proteins in aggresomes is not surprising: The large size of mammalian cells, together with the presence of the cytoskeleton, a structure that could restrict the motility of particulate material (Gershon et al. 1985) , implies that non-difussional mechanisms are needed to sequester aggregates within the cytoplasm and transport them to the MTOC. For that purpose, formation of aggresomes must exploit the transport on microtubules (Garcia-Mata et al. 1999; Johnston et al. 2002; Kopito 2000; Kopito and Sitia 2000) , resulting in the fact that cytoskeleton-related proteins, like vimentin, tubulin, actin, and others, are usually found intimately associated with aggresomes. It has been shown that small aggregates generated at the cell periphery are transported within the cytoplasm at a rate of 0.32 μm/min toward the aggresome (Garcia-Mata et al. 1999) . A model for microtubule-based delivery of protein aggregates to aggresomes has been described (Kopito 2000; Kopito and Sitia 2000) . In agreement with our results, the presence of γ-tubulin has been described, as an aggresome-related protein in α-synuclein-containing aggresomes (Chiba et al. 2012 ) and in perinuclear aggregate bodies formed by a truncated protein containing expanded polyQ stretches (Shimohata et al. 2002) . All these studies corroborate our findings about the presence of Hsp70 chaperone, actin, and tubulin as aggresome-related proteins.
Finally, aggresomes showed protection of the sequestered form of the enzyme within the aggresome fraction toward thermal inactivation in solution and, in our testing system, could be reused at least up to five rounds of consecutive enzymatic assays (Fig. 5) .
The proof-of-concept shown here of aggresomes as immobilized biofunctional particles could be in the line of the development of a new type of biomaterial, similarly to the application of bacterial IBs as protein release nanoparticles in tissue engineering and substitutive therapies (SerasFranzoso et al. 2013a (SerasFranzoso et al. , b, 2014 . Since some eukaryotic proteins are not produced in their active form when expressed in prokaryotic systems, mammalian aggresomes could be an alternative to package functional proteins in mechanically stable, protein-releasing nano-microstructured materials. GLA glycosylation itself has been described as crucial to the enzyme activity (Ioannou et al. 1998) , hampering their production in bacterial expression systems. In this context, it has been possible to adapt a purification protocol for aggresomes to the peculiar functional demands of aggresomes (mainly its optimal pH for catalytic activity). In summary, since mammalian cell aggresomes retain the enzymatic activity of their protein components, show improved stability versus soluble protein versions, and can be purified by function-friendly protocols, we propose these structures as a novel type of carrier-free, self-assembled immobilized biomaterial, with putative applications in biotechnology and biomedicine. This strategy could be of special interest for those proteins that, like GLA, cannot be expressed in prokaryotic systems. The model GLA used in this work formed enzymatically active aggresomes, representing a proof-of-concept for such aggregates as a new type of carrier-free, self-assembled immobilized biomaterial. However, in addition, α-galactosidases are also of particular interest regarding biotechnological and biomedical applications, and GLA aggresomes could have putative applications in both biotechnological (such as the removal of raffinose oligosaccharides from several legume-based foods) and biomedical fields (such as improved methods to deliver enzymatically active GLA in the field of innovative enzyme replacement therapies in Fabry disease patients).
